Nationwide drug-dispensing data reveal important differences in adherence to drug label recommendations on CYP2D6-dependent drug interactions

British Journal of Clinical Pharmacology

Volumn 69, Issue 4, 2010, Pages 411-417

  Mannheimer, Buster ^a   Wettermark, Björn ^b,d   Lundberg, Michael ^c   Pettersson, Hans ^d   Von Bahr, Christer ^d   Eliasson, Erik ^d  

^a KAROLINSKA INSTITUTE   (Sweden)

^b Network for Pharmacoepidemiology Foundation   (Sweden)

^c CENTRE FOR EPIDEMIOLOGY   (Sweden)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Adverse drug reactions; Bioactivation; Drug metabolism; Drug prescribing; Pharmacoepidemiology; Therapeutic failure

Indexed keywords

ANASTROZOLE; ATENOLOL; CITALOPRAM; CODEINE; CYTOCHROME P450 2D6; DEXTROPROPOXYPHENE; DONEPEZIL; ESCITALOPRAM; FLUOXETINE; GALANTAMINE; METOPROLOL; PAROXETINE; PRODRUG; RIVASTIGMINE; SERTRALINE; TAMOXIFEN;

ADOLESCENT; ADULT; ARTICLE; CLINICAL PRACTICE; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG ELIMINATION; DRUG LABELING; DRUG METABOLISM; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; MALE; PHARMACOEPIDEMIOLOGY; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SWEDEN; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; AGED, 80 AND OVER; ANALGESICS, OPIOID; CHOLINESTERASE INHIBITORS; CROSS-SECTIONAL STUDIES; CYTOCHROME P-450 CYP2D6; DEPRESSIVE DISORDER; DRUG INTERACTIONS; DRUG PRESCRIPTIONS; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; RETROSPECTIVE STUDIES; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SEROTONIN UPTAKE INHIBITORS; SWEDEN; YOUNG ADULT;

EID: 77949392893     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2009.03598.x     Document Type: Article

References (38)

1. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, Farrar K, Park PK, Breckenridge AM. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 2004; 329: 15-9.
2. Becker ML, Kallewaard M, Caspers PW, Visser LE, Leufkens HG, Stricker BH. Hospitalisations and emergency department visits due to drug-drug interactions: a literature review. Pharmacoepidemiol Drug Saf 2007; 16: 641-51.
3. Wilkinson GR. Drug metabolism and variability among patients in drug response. N Engl J Med 2005; 352: 2211-21.
4. FDIUDom. Drug Interaction Table. Available at http://medicine.iupui.edu/ flockkhart/table.htm (last accessed 23 October 2009).
5. Molden E, Garcia BH, Braathen P, Eggen AE. Co-prescription of cytochrome P450 2D6/3A4 inhibitor-substrate pairs in clinical practice. A retrospective analysis of data from Norwegian primary pharmacies. Eur J Clin Pharmacol 2005; 61: 119-25.
6. Tirkkonen T, Laine K. Drug interactions with the potential to prevent prodrug activation as a common source of irrational prescribing in hospital inpatients. Clin Pharmacol Ther 2004; 76: 639-47.
7. Davies SJ, Eayrs S, Pratt P, Lennard MS. Potential for drug interactions involving cytochromes P450 2D6 and 3A4 on general adult psychiatric and functional elderly psychiatric wards. Br J Clin Pharmacol 2004; 57: 464-72.
8. Gregor KJ, Way K, Young CH, James SP. Concomitant use of selective serotonin reuptake inhibitors with other cytochrome P450 2D6 or 3A4 metabolized medications: how often does it really happen? J Affect Disord 1997; 46: 59-67.
9. Preskorn SH. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clin Pharmacokinet 1997; 32 (Suppl. 1): 1-21.
10. FASS. The Swedish Catalogue of Approved Medical Products. 2008.
11. Wettermark B, Hammar N, Fored CM, Leimanis A, Otterblad Olausson P, Bergman U, Persson I, Sundström A, Westerholm B, Rosén M. The new Swedish Prescribed Drug Register - opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf 2007; 16: 726-35.
12. Rahman M, Lax SF, Sutter CH, Tran QT, Stevens GL, Emmert GL, Russo J, Santen RJ, Sutter TR. CYP1B1 is not a major determinant of the disposition of aromatase inhibitors in epithelial cells of invasive ductal carcinoma. Drug Metab Dispos 2008; 36: 963-70.
13. Marsh S, McLeod HL. Pharmacogenetics and oncology treatment for breast cancer. Expert Opin Pharmacother 2007; 8: 119-27.
14. Hemeryck A, Lefebvre RA, De Vriendt C, Belpaire FM. Paroxetine affects metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers. Clin Pharmacol Ther 2000; 67: 283-91.
15. Reeves PR, McAinsh J, McIntosh DA, Winrow MJ. Metabolism of atenolol in man. Xenobiotica 1978; 8: 313-20.
16. Mannens GS, Snel CA, Hendrickx J, Verhaeghe T, Le Jeune L, Bode W, van Beijsterveldt L, Lavrijsen K, Leempoels J, Van Osselaer N, Van Peer A, Meuldermans W. The metabolism and excretion of galantamine in rats, dogs, and humans. Drug Metab Dispos 2002; 30: 553-63.
17. Aricept. Pharmaca Fennica. Helsinki: Pharmaceutical Information Centre, 2004.
18. Bentue-Ferrer D, Tribut O, Polard E, Allain H. Clinically significant drug interactions with cholinesterase inhibitors: a guide for neurologists. CNS Drugs 2003; 17: 947-63.
19. Sindrup SH, Brosen K, Bjerring P, Arendt-Nielsen L, Larsen U, Angelo HR, Gram LF. Codeine increases pain thresholds to copper vapor laser stimuli in extensive but not poor metabolizers of sparteine. Clin Pharmacol Ther 1990; 48: 686-93.
20. Poulsen L, Brosen K, Arendt-Nielsen L, Gram LF, Elbaek K, Sindrup SH. Codeine and morphine in extensive and poor metabolizers of sparteine: pharmacokinetics, analgesic effect and side effects. Eur J Clin Pharmacol 1996; 51: 289-95.
21. Desmeules J, Gascon MP, Dayer P, Magistris M. Impact of environmental and genetic factors on codeine analgesia. Eur J Clin Pharmacol 1991; 41: 23-6.
22. Goetz MP, Knox SK, Suman VJ, Rae JM, Safgren SL, Ames MM, Visscher DW, Reynolds C, Couch FJ, Lingle WL, Weinshilboum RM, Fritcher EG, Nibbe AM, Desta Z, Nguyen A, Flockhart DA, Perez EA, Ingle JN. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat 2007; 101: 113-21.
23. Goetz MP, Rae JM, Suman VJ, Safgren SL, Ames MM, Visscher DW, Reynolds C, Couch FJ, Lingle WL, Flockhart DA, Desta Z, Perez EA, Ingle JN. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 2005; 23: 9312-8.
24. Somogyi AA, Menelaou A, Fullston SV. CYP3A4 mediates dextropropoxyphene N-demethylation to nordextropropoxyphene: human in vitro and in vivo studies and lack of CYP2D6 involvement. Xenobiotica 2004; 34: 875-87.
25. WHO. Guidelines for ATC classification and DDD assignment. 2008. Available at http://www.whocc.no (last accessed 23 October 2009).
26. Statistiska Centralbyrån (SCB). Statistics Sweden. 2009. Available at http://www.scb.se/Pages/List-250612.aspx (last accessed 23 October 2009).
27. Meijer WE, Heerdink ER, Pepplinkhuizen LP, van Eijk JT, Leufkens HG. Prescribing patterns in patients using new antidepressants. Br J Clin Pharmacol 2001; 51: 181-3.
28. Swedish Breast Cancer. Group guidelines. 2009. Available at http://www.swebcg.se/Files/Docs/Nationella-riktlinjer091027.pdf (last accessed 13 December 2009).
29. Kurtz DL, Bergstrom RF, Goldberg MJ, Cerimele BJ. The effect of sertraline on the pharmacokinetics of desipramine and imipramine. Clin Pharmacol Ther 1997; 62: 145-56.
30. Solai LK, Mulsant BH, Pollock BG, Sweet RA, Rosen J, Yu K, Reynolds CF 3rd. Effect of sertraline on plasma nortriptyline levels in depressed elderly. J Clin Psychiatry 1997; 58: 440-3.
31. Spina E, Scordo MG, D'Arrigo C. Metabolic drug interactions with new psychotropic agents. Fundam Clin Pharmacol 2003; 17: 517-38.
32. Bjerrum L, Rosholm JU, Hallas J, Kragstrup J. Methods for estimating the occurrence of polypharmacy by means of a prescription database. Eur J Clin Pharmacol 1997; 53: 7-11.
33. Lau HS, de Boer A, Beuning KS, Porsius A. Validation of pharmacy records in drug exposure assessment. J Clin Epidemiol 1997; 50: 619-25.
34. Preskorn SH, Shah R, Neff M, Golbeck AL, Choi J. The potential for clinically significant drug-drug interactions involving the CYP 2D6 system: effects with fluoxetine and paroxetine versus sertraline. J Psychiatr Pract 2007; 13: 5-12.
35. Mannheimer B, Ulfvarson J, Eklof S, Bergqvist M, von Bahr C. A clinical evaluation of the Janus Web Application, a software screening tool for drug-drug interactions. Eur J Clin Pharmacol 2008; 64: 1209-14.
36. Bottiger Y, Laine K, Andersson ML, Korhonen T, Molin B, Ovesjö ML, Tirkkonen T, Rane A, Gustafsson LL, Eiermann B. SFINX - a drug-drug interaction database designed for clinical decision support systems. Eur J Clin Pharmacol 2009; 65: 627-33.
37. Magnus D, Rodgers S, Avery AJ. GPs' views on computerized drug interaction alerts: questionnaire survey. J Clin Pharm Ther 2002; 27: 377-82.
38. Mille F, Schwartz C, Brion F, Fontan JE, Bourdon O, Degoulet P, Jaulent MC. Analysis of overridden alerts in a drug-drug interaction detection system. Int J Qual Health Care 2008; 20: 400-5.